<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62974">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02286089</url>
  </required_header>
  <id_info>
    <org_study_id>CCN_CT02</org_study_id>
    <nct_id>NCT02286089</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration</brief_title>
  <official_title>Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cell Cure Neurosciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cell Cure Neurosciences Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is evaluation of the safety and tolerability of OpRegen -
      human embryonic stem cell-derived retinal pigment epithelial (RPE)cells. The study will also
      include initial exploration of the ability of transplanted OpRegen cells to engraft,
      survive, and moderate disease progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OpRegenÂ® is a cell-based product composed of retinal pigment epithelial (RPE) cells, derived
      from human embryonic stem cells (hESC) and administered as a cell suspension in ophthalmic
      Balanced Salt Solution Plus (BSS Plus).

      This is a Phase I/IIa, dose-escalation, single-center study, evaluating safety and
      tolerability of OpRegen transplantation to patients with progressive dry-AMD. The study
      includes also initial exploration of efficacy.

      A total of 15 patients will be enrolled. The patients should be 50 years of age and older,
      with non-neovascular (dry) AMD, who have funduscopic findings of GA in the macula, with
      absence of additional concomitant ocular disorders.

      The patients will be divided into four cohorts, according to their best corrected visual
      acuity (BCVA) and administrated OpRegen dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and frequency of treatment emergent adverse events</measure>
    <time_frame>12 months post transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment emergent changes of clinical and opthalmological parameters</measure>
    <time_frame>12 months post transplantation</time_frame>
    <description>The following measurements will be performed:
Vital signs
Hematology/ Blood Chemistry/Urinalysis
Physical examination
Ophthalmological evaluations, such as (not limited to):
Dilated Fundus Exam and Retinal Fundus Imaging
Intraocular Pressure
Slit Lamp Examination
Spectral Domain Optical Coherence Tomography
Fluorescein Angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in GA lesion area (sqr. mm)</measure>
    <time_frame>12 months post transplantation</time_frame>
    <description>Measurement of change in GA lesion area will be performed based on available imaging data by a central reading center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visual acuity</measure>
    <time_frame>12 months post transplantation</time_frame>
    <description>Change in visual acuity will be measured by ETDRS chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>12 months post transplantation</time_frame>
    <description>Change in NEI VFQ-25 Quality of Life score will be measured from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>OpRegen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 legally blind patients with best corrected visual acuity of 20/200 or less in first three cohorts and 6 patients with best corrected visual acuity of 20/100 or less in fourth cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OpRegen</intervention_name>
    <description>Targeted dose of 50,000 - 500,000 cells will be delivered into the subretinal space following vitrectomy procedure</description>
    <arm_group_label>OpRegen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 50 and older;

          2. Diagnosis of dry (non-neovascular) age related macular degeneration in both eyes;

          3. Funduscopic findings of dry AMD with progressive geographic atrophy in the macula,
             above 0.5 disc area (1.25mm^2 and up to 17 mm^2) in size in the study eye and above
             0.5 disc area in the fellow eye;

          4. Best corrected central visual acuity equal or less than 20/200 in cohorts 1-3 and
             equal or less than 20/100 in cohort 4 in the study eye by ETDRS vision testing;

          5. Vision in the non-operated eye must be better than or equal to that in the operated
             eye;

          6. Patients with sufficiently good health to allow participation in all study-related
             procedures and complete the study follow up period (medical records);

          7. Ability to undergo a vitreoretinal surgical procedure under monitored anesthesia
             care;

          8. Blood counts, blood chemistry, coagulation and urinalysis without abnormal
             significance;

          9. Negative for HIV, HBC, and HCV, negative for CMV IgM and EBV IgM;

         10. Patients with no current or history of malignancy (with the exception of successfully
             treated basal/squamous cell carcinoma of the skin) based on age matched screening
             exam (at discretion of the study physician);

         11. Willing to defer all future blood and tissue donation;

         12. Able to understand and willing to sign informed consent.

        Exclusion Criteria:

          1. Evidence of neovascular AMD by history, as well as by clinical exam, fluorescein
             angiography (FA), or ocular coherence tomography (OCT) at baseline in either eye;

          2. History or presence of diabetic retinopathy, vascular occlusions, uveitis, Coat's
             disease, glaucoma, cataract or media opacity preventing posterior pole visualization
             or any significant ocular disease other than AMD that has compromised or could
             compromise vision in the study eye and confound analysis of the primary outcome;

          3. History of retinal detachment repair in the study eye;

          4. Axial myopia greater than -6 diopters;

          5. Cataract Surgery in the study eye in the past 6 weeks and any other ocular surgery in
             the study eye in the past 3 months

          6. History of cognitive impairments or dementia;

          7. Contraindication for systemic immunosuppression;

          8. History of any condition other than AMD associated with choroidal neovascularization
             in the study eye (e.g. pathologic myopia or presumed ocular histoplasmosis);

          9. Active or history for the following diseases: cancer, renal disease, myocardial
             infraction in previous 12 months, immunodeficiency;

         10. Female; pregnancy or lactation;

         11. Current participation in another clinical study. Past participation (within 6 months)
             in any clinical study of a drug administered systemically or to the eye.

         12. Currently receiving aspirin, aspirin containing products and/or any other coagulation
             modifying drugs which cannot be discontinued 7 days prior to surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Gurevich</last_name>
    <role>Study Director</role>
    <affiliation>Cell Cure Neurosciences Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tareq Jaouni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Ein Kerem University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dov Weinberger, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayala Pollack, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaplan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adiel Barak, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv Souraski Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Devora Marks Ohana</last_name>
    <phone>972-2-6776324</phone>
    <email>dryamdstudy@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vivi Dagan</last_name>
    <phone>972-3-9377199</phone>
    <email>eyeclinic@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah Ein Kerem University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devora Marks Ohana</last_name>
      <phone>972-2-6776324</phone>
      <email>dryamdstudy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tareq Jaouni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuval Tal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eyal Banin, MD, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ytzhak Hemo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivi Dagan</last_name>
      <phone>972-3-9377199</phone>
      <email>eyeclinic@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Dov Weinberger, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruth Siegel, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irit Rosenblat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita Ehrlich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iris Daitch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Herrado Morvenik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irena Srov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michal Shahaf-Fogler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Orly Gal Or, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kfir Tal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Scwartzberg</last_name>
      <phone>972-8-9441691</phone>
      <email>kaplaneye1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ayala Pollack, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haia Morori-Katz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amir Bukelman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reut Parness-Yosifon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oren Yovel-Shmuel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yoel Greenwald, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Goz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guy Kleinman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arie Marcovich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tamir Vainberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Souraski Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>91121</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sagit Bechor</last_name>
      <phone>03-6974361</phone>
      <email>sagitba@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Adiel Barak, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anat Loewenstein, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michaela Goldshtein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shiri Shulman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Regenbogen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sholamit Shortz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hadas Nueman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zohar Habot-Wilner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nurit Erlich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dina Zur, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Efrat Flysing, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nor Azam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Martinez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Idelson M, Alper R, Obolensky A, Ben-Shushan E, Hemo I, Yachimovich-Cohen N, Khaner H, Smith Y, Wiser O, Gropp M, Cohen MA, Even-Ram S, Berman-Zaken Y, Matzrafi L, Rechavi G, Banin E, Reubinoff B. Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells. Cell Stem Cell. 2009 Oct 2;5(4):396-408. doi: 10.1016/j.stem.2009.07.002.</citation>
    <PMID>19796620</PMID>
  </reference>
  <reference>
    <citation>Tannenbaum SE, Turetsky TT, Singer O, Aizenman E, Kirshberg S, Ilouz N, Gil Y, Berman-Zaken Y, Perlman TS, Geva N, Levy O, Arbell D, Simon A, Ben-Meir A, Shufaro Y, Laufer N, Reubinoff BE. Derivation of xeno-free and GMP-grade human embryonic stem cells--platforms for future clinical applications. PLoS One. 2012;7(6):e35325. doi: 10.1371/journal.pone.0035325. Epub 2012 Jun 20.</citation>
    <PMID>22745653</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 14, 2017</lastchanged_date>
  <firstreceived_date>November 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dry-AMD</keyword>
  <keyword>Geographic Atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
